Mbhs

[mickymoose99]

mBeach Software Inc. Extends Global Patent Protection
.
Companies:MBEACH SOFTWARE INC.Related Quotes
Symbol Price Change
MBHS.OB 0.31 0.00


{"s" : "mbhs.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: mBeach Software Inc. On Tuesday August 31, 2010, 4:00 pm EDT

TEL AVIV, Israel, Aug. 31, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today announced the filing of additional patent applications under the framework of the Patent Cooperation Treaty (PCT). This move will facilitate the company's strategy to enter new international markets for its advanced, non-invasive system to detect and identify skin cancer.



Skin Cancer Scanning Ltd. ("SCS"), the wholly owned subsidiary, has already submitted a patent application in the United States (application number 11/464,838) with a priority date of August 2006. The patent office is currently examining this application and the company expects the patent to be approved and published by the end of 2010.



In addition to the United States, SCS has extended its patent applications in many important markets around the world. These countries include Canada, Japan, Australia, China, South Korea, New Zealand, Israel, South Africa, Brazil, Mexico, Russia and the Commonwealth of Independent States (CIS), Ukraine, and the European Union. These patent applications have now reached the national phase of registration.



These Patent applications are now at the stage of being translated into the relevant national languages of the various countries mentioned.



This is the stage before entering final review by each country's patent examination committees.



"Our intellectual property is one of the company's most valuable assets," said mBeach CEO Yossi Biderman. "We are taking all necessary measures to protect this asset, including patent applications and other appropriate actions. International growth is an important part of our strategy for growth. We want to make sure we have the right patent protection in all our major potential markets as soon as possible."



About SCS



Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.



Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.



For more information on SCS, visit Skin Cancer Scanning Ltd. (SCS) :: Symbol (OTCBB): MBHS.



Forward Looking Statements

[mickymoose99]

mBeach Software Inc. Issues Stockholder Update
.
Companies:MBEACH SOFTWARE INC.Related Quotes
Symbol Price Change
MBHS.OB 0.32 +0.03


{"s" : "mbhs.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: mBeach Software Inc. On Tuesday September 7, 2010, 4:00 pm EDT

TEL AVIV, Israel, Sept. 7, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update. The Company believes in the importance of regular communication and timely information delivered to investors. To this end, mBeach is committed to share with its stockholders release regular updates on its progress.



mBeach, through its wholly owned subsidiary Skin Cancer Scanning Ltd. ("SCS") is pioneering the development and commercialization of a revolutionary and proprietary diagnostic device for the early detection and diagnosis of skin cancer. Our product, an advanced stage prototype, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers.



To date, we have successfully conducted two stages of clinical trials. The results from 128 scanned nevi demonstrated 92.4% accuracy in diagnosing non-melanoma skin cancer (NMSC). These results are significantly higher than the 75% accuracy achieved by an experienced dermatologist and 60% accuracy achieved by a general practitioner.



These initial results were gained by operating the device in the visual range (the light that we can see with an unaided eye) of the light spectrum.



We expect that further development of the devices' capabilities, into the Infra Red range, will dramatically improve results in diagnosing both Melanoma and Non Melanoma Skin Cancer.



We intend to complete the second stage development by July 2011. This will enable us to introduce into the market our SkinScan 650 diagnostic device with its full capabilities.



Our medical device, SkinScan 650's state-of-the-art technology will enable physicians to improve their diagnostic abilities using SkinScan 650. This will replace current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and lower chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.



For more information on SCS, visit the company's new website at Skin Cancer Scanning Ltd. (SCS) :: Symbol (OTCBB): MBHS

[mickymoose99]

mBeach Software Inc. Restructuring

Share
retweet
EmailPrint..Companies:MBEACH SOFTWARE INC.Related Quotes
Symbol Price Change
MBHS.OB 0.3200 0.0000


{"s" : "mbhs.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00", "o" : "","j" : ""} Press Release Source: mBeach Software Inc. On Wednesday September 8, 2010, 9:00 am

TEL AVIV, Israel, Sept. 8, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) announced today plans to redefine the activities of MBHS and Skin Cancer Scanning Ltd. (SCS). This follows the July 15 announcement of the closure of the merger with SCS, as a result of which MBHS holds 100% of SCS.



This new plan defines how each company will focus on its core competence activities, with the goal of maximizing synergies, and creating stronger shareholder value.



Under the new plan, SCS will focus on its core competencies of research and development, regulatory issues, and conducting further clinical trials in Israel. MBHS will focus on worldwide business and marketing activities.



The former management of MBHS has been entirely replaced by a new management, including members of the former SCS management. The new team combines leading scientific and technical experts as well as international marketing experience and expertise.



Col. Yossi Biderman, MBHS's new CEO, stated, "We feel this new restructuring of mBeach and SCS will best leverage the core competencies of each company. This follows our strategy to increase synergies between the companies and grow total shareholder value. We believe this move will strengthen the company and enable us to succeed in the global market for advanced technologies to better detect skin cancers."



About SCS



Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.



Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.



For more information on SCS, visit Skin Cancer Scanning Ltd. (SCS) :: Symbol (OTCBB): MBHS.

[kattywilliams]

This newsletter is a sure guide to your great success in terms of stock picks.

pennyalerts./info

Copy and paste the link above without the / to get MORE info